GLP-1 Drugs Linked to Better Breast Cancer Outcomes in Obesity and Diabetes Patients

A recent study published in JAMA Network Open suggests that GLP-1 receptor agonists (GLP-1RA), including medications like Ozempic, Wegovy, and Mounjaro, may improve survival rates and lower the risk of recurrence in breast cancer patients with obesity or type 2 diabetes.

The findings indicate that GLP-1 drugs were associated with a reduced risk of mortality compared to insulin or metformin alone in individuals with type 2 diabetes. Breast cancer remains one of the most prevalent cancers in the U.S., accounting for 30% of all new female cancer cases annually.

Patients with breast cancer who also have obesity or type 2 diabetes often face lower survival rates. However, the study highlights a potential benefit of GLP-1 medications in this high-risk group.

Key Study Findings

• GLP-1 drugs were linked to improved breast cancer survival rates in patients with obesity, type 2 diabetes, or both.
• The study suggests a lower risk of cancer recurrence among users of GLP-1 medications.
• GLP-1 receptor agonists were compared favorably to insulin and metformin in reducing mortality risk for those with type 2 diabetes.

Expert Insights

Lead study author Kristina L. Tatum, PsyD, MS, an instructor in the Department of Social and Behavioral Sciences at Virginia Commonwealth University’s School of Public Health, emphasized the significance of the findings:

“

[Breast cancer] patients with obesity or pre-existing type 2 diabetes often face more complex breast cancer journeys. Our findings are encouraging because they suggest that GLP-1RA use may be associated with improved survival and lower recurrence among these patients.

While causation cannot be confirmed from this observational study, the findings provide important data for clinicians and patients with obesity and/or type 2 diabetes to consider as we continue to learn more about the possibilities of GLP-1RA therapies in breast cancer survivorship.”

Obesity and Breast Cancer: The Connection

Obesity is a well-documented risk factor for breast cancer and is associated with higher recurrence rates. Fat tissue produces estrogen, which can promote the growth of certain breast cancer subtypes. By reducing body weight and fat mass, GLP-1 medications may help lower these risks.

Amy Bremner, MD, a breast surgical oncologist and medical director of breast surgical oncology at MemorialCare Saddleback Medical Center in Laguna Hills, California, who was not involved in the study, commented on the potential implications:

“

We know that obesity is well-established as an obesity-associated cancer risk factor. Fat produces estrogen, which promotes certain breast cancer subtypes. By reducing body weight and fat mass, this could potentially reduce recurrence risk.”

The study’s co-author, Bernard F. Fuemmeler, PhD, MPH, a professor and Gordon D. Laing Distinguished Chair at the University of Chicago, added that the research underscores the broader health impacts of GLP-1 medications beyond diabetes and weight management.

Broader Implications of GLP-1 Drugs

GLP-1 medications have gained significant attention for their effectiveness in treating obesity and type 2 diabetes. Approximately 1 in 8 U.S. adults has used a GLP-1 drug such as Ozempic or Wegovy, including 40% of those with diabetes and 25% of those with heart disease.

As these drugs become more widely prescribed, researchers are increasingly exploring their potential benefits in other areas, including cancer survivorship. However, the authors stress that further research is needed to confirm these findings and understand the underlying mechanisms.